May 16th 2024
Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Researchers Develop Improved Flow Cytometric Score for MDS Diagnosis
January 16th 2021A flow cytometric score developed in 2012, which uses 4 parameters to distinguish low-grade myelodysplastic syndromes (MDS) from nonclonal cytopenias, is simple and practical for screening patients with MDS, according to research published in the American Journal of Translational Research.
Read More
Analysis Reveals High Cost of Discontinued HMA Treatment for MDS
January 15th 2021New research underscores the substantial economic burden associated with early discontinuation of guideline-recommended hypomethylating agent (HMA) therapy among patients with refractory anemia with excess blasts, a diagnosis that substantially overlaps with higher-risk myelodysplastic syndrome (MDS).
Read More
Study Finds IWG 2006 Response Criteria Valid in Patients With Higher-Risk MDS
January 7th 2021Complete response to first-line therapy, as determined by the International Working Group 2006 response criteria, can be used as a surrogate end point for overall survival in higher-risk patients with myelodysplastic syndromes (MDS), according to a study published in Cancer Medicine.
Read More
Is a New Classification and Prognosis System Possible for Myelodysplastic Syndromes?
January 2nd 2021Integrating novel parameters into conventional risk stratification systems may better define patient subgroups in myelodysplastic syndromes (MDS), thus creating a more enhanced classification and prognostic scoring system for patients, say researchers.
Read More
Unanswered Questions Remain in Optimal Management of RBC Transfusions in MDS
January 1st 2021Questions remain about the optimal approach to transfusion management in myelodysplastic syndromes (MDS), particularly in the outpatient setting, leading a pair of researchers to review current evidence.
Read More
Heterogenous Nature of MDS Warrants Further Research, Review Finds
December 23rd 2020With a goal of moving toward more individualized therapeutic approaches, researchers said future advancements in understanding myelodysplastic syndrome (MDS) molecular mechanisms are needed to offer clinical decision making guidance.
Read More
Gene Expression Signatures Linked With Response to HMA Treatment in Patients With MDS
December 19th 2020Their work may help to further understanding of the molecular mechanisms of hypomethylating agents (HMAs) and offer a guide for determining which patients are likely to respond to such treatment.
Read More
For Patients With HMA-Resistant MDS, What Are Their Options?
December 18th 2020For patients who are resistant to hypomethylating agent (HMA) treatment, there are no formal treatment recommendations, but several options, spanning from novel HMAs to chemotherapy, have been or are currently being studied in the setting.
Read More
Study Finds Significant Survival Advantage for Patients With MDS Who Have HLA-Matched Donor for HCT
December 12th 2020The abstract, presented at the 2020 American Society of Hematology Annual Meeting and Exposition, found favorable overall survival and leukemia-free survival for these patients.
Read More
Dr Abby Statler Speaks on Eligibility Criteria Exclusions for MDS Clinical Trials
February 21st 2020Our outcomes suggest that eligibility criteria for patients with MDS relevant to liver function, renal function, and comorbidities may be relaxed, especially for those who have minor renal function abnormalities who have shown to have similar clinical outcomes to those without such abnormalities, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.
Watch
Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS
December 28th 2018Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.
Read More
Early Data Suggests CC-486 Relatively Safe, Effective in Thrombocytopenic Patients With MDS
November 21st 2018There have been few therapeutic options for treating thrombocytopenia in MDS patients. Now, early phase data suggest that CC-486 (oral azacytidine, an investigational drug sponsored by Celgene) is a relatively safe and effective treatment for thrombocytopenic patients with MDS.
Read More